Shares in Tamir Capital are soaring on lively volumes, following a Tel Aviv District Court ruling that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) infringed the terms of a license from Proneuron Biotechnologies, and that the intellectual property rights should be restored to Proneuron immediately. Teva was also ordered to pay costs of about $100, 000.
The judge found that “Teva made a mistaken professional decision and embarked on an efficacy trial that was not well planned, since it ought to have given greater weight to the pre-clinical findings and to have examined their significance further before starting a clinical trial.”… [READ MORE]
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Published by Globes [online], Israel business news – www.globes-online.com
